Upcoming AWS Coverage on 3D Systems Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. announces its post-earnings coverage on Stratasys Ltd. (NASDAQ: SSYS). The Company disclosed its financial results for the fourth quarter fiscal 2017 (Q4 FY16) and full year fiscal 2017 (FY16) on March 09, 2017. The Minneapolis & Rehovot, Israel-based Company’s quarterly revenues increased on a year-over-year basis, outperforming market consensus estimates. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Stratasys’ competitors within the Computer Peripherals space, 3D Systems Corp. (NYSE: DDD), reported on February 28, 2017, its fourth quarter and full year 2016 financial results. AWS will be initiating a research report on 3D Systems in the coming days.

Today, AWS is promoting its earnings coverage on SSYS; touching on DDD. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

Stratasys reported total revenue of $175.30 million in Q4 FY16, which came in marginally above the $173.36 million recorded in Q4 FY15. Total revenue numbers for Q4 FY16 topped market forecasts of $169.8 million. Meanwhile, the Company’s consumable revenues were up 11% y-o-y in the reported quarter.

The 3D printers maker’s GAAP net loss attributable to Stratasys came in at $14.76 million, or $0.30 loss per diluted share, in Q4 FY16 compared to GAAP net loss attributable to Stratasys of $232.34 million, or $4.46 loss per diluted share, in Q4 FY15. Meanwhile, the Company reported non-GAAP net income attributable to Stratasys of $7.83 million, or $0.15 per diluted share, in Q4 FY16 versus non-GAAP net loss attributable to Stratasys of $0.70 million, or $0.01 loss per diluted share, in Q4 FY15. Wall Street had expected the Company to report non-GAAP net income of $0.05 per diluted share.

In FY16, Stratasys’ total revenue came in at $672.46 million compared to $696.00 million in the previous year. The Company reported GAAP net loss attributable to Stratasys of $77.22 million, or $1.48 loss per diluted share, in FY16 versus GAAP net loss attributable to Stratasys of $1.37 billion, or $26.64 per diluted share, in FY15. Furthermore, the Company’s non-GAAP net income attributable to Stratasys during FY16 was $14.77 million, or $0.28 per diluted share, compared to $9.95 million, or $0.19 per diluted share, in FY15.

Operating Metrics

In Q4 FY16, the Company’s GAAP gross profit improved to $82.92 million, or 47.3% of revenue, from $53.07 million, or 30.6% of revenue, in the year ago same period. Moreover, the Company’s non-GAAP gross profit increased to $94.02 million, or 53.6% of revenue in Q4 FY16 from $83.38 million, or 48.1% of revenue, in the year ago comparable period. In Q4 FY16, the Company spent $24.30 million on R&D expenses compared to $31.92 million in Q4 FY15.

Stratasys’ GAAP operating loss narrowed in Q4 FY16 to $29.17 million from $187.81 million in the prior year’s corresponding period. Furthermore, the Company reported non-GAAP operating income of $11.57 million in Q4 FY16 against non-GAAP operating loss of $8.88 million in Q4 FY15.

Segment Performance

During Q4 FY16, products revenue increased 2% to $126.56 million from $124.32 million in the previous year’s comparable quarter. The segment’s GAAP gross margin improved to 51.0% in Q4 FY16 from 30.2% in the prior year’s same quarter. Additionally, the segment’s non-GAAP gross margin rose to 59.5% in Q4 FY16 from 52.8% in Q4 FY15.

Services contributed $48.75 million to total revenue in Q4 FY16 compared to $49.05 million in Q4 FY15. The segment’s GAAP gross margin for Q4 FY16 was 37.6% versus $31.6% of in previous year’s comparable quarter. Additionally, the segment reported non-GAAP gross margin of 38.3% in Q4 FY16 compared to 36.2% in Q4 FY15.

Cash Flow and Balance Sheet

In the quarter ended December 31, 2016, net cash provided by operating activities surged to $26.0 million from $7.7 million in Q4 FY15. As on December 31, 2016, the Company had cash and cash equivalents balance of $280.33 million compared to a balance of $257.59 million as on December 31, 2015. The Company reported long-term debt of $22.29 million in its books of accounts as on December 31, 2016, while it did not report any long-term debt in the year ago period.

Earnings Outlook

In its guidance for FY17, Stratasys’ expects total revenues in the range of $645 million to $680 million. The Company anticipates FY17 non-GAAP operating margins to be between 3% and 5%. FY17 non-GAAP net income is projected to be in range of $10 million to $20 million, or $0.19 per diluted share to $0.37 per diluted share. Furthermore, the Company expects GAAP net loss of $53 million to $39 million, or a ($1.00) per diluted share to ($0.73) per diluted share, in FY17.

Stock Performance

At the close of trading session on Thursday, March 23, 2017, Stratasys’ stock price climbed 1.92% to end the day at $19.15. A total volume of 568.17 thousand shares were exchanged during the session. The Company’s share price has gained 15.78% on an YTD basis. The stock currently has a market cap of $1.01 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458088

Upcoming AWS Coverage on CyrusOne Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. announces its post-earnings coverage on Investors Real Estate Trust (NYSE: IRET) as the Company reported its financial results for its third quarter fiscal 2017 on March 13, 2017. The Minot, North Dakota based real estate investment trust missed markets FFO estimates. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Investors Real Estate Trust’s competitors within the REIT – Diversified space, CyrusOne Inc. (NASDAQ: CONE), reported on February 22, 2017, its Q4 and full year 2016 earnings. AWS will be initiating a research report on CyrusOne in the coming days.

Today, AWS is promoting its earnings coverage on IRET; touching on CONE. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

For the quarter ended January 31, 2017, IRET’s total revenue was $51.17 million, up 5.7% from Q3 FY16 revenue of $48.41 million.

IRET’s net operating income (NOI) from all properties increased by approximately $296,000, or 1.1%, for Q3 FY17 compared to the same period one year ago. Non-same-store properties, primarily multifamily developments, provided for an increase in NOI of $1.6 million while same-store NOI dropped by $1.3 million for the reported quarter.

For Q3 FY17, IRET’s net income available to common shareholders was $19.2 million compared to $36.9 million for Q3 FY16. The decrease of $17.7 million was primarily due to net gain on extinguishment of debt in discontinued operations that was recognized in the comparable period of $36.5 million, net of an increase in gains on sale of discontinued operations of $19.2 million.

IRET’s reported Funds from Operations (“FFO”) for the quarter ending January 31, 2017, was $12.66 million, or $0.09 per share/unit. Excluding one-time items, including a $1.9 million loss on extinguishment of debt primarily related to the new line of credit and $1.4 million of redemption costs for the Series A preferred shares, FFO would have been $0.12 per share/unit. The Company’s FFO numbers came in below market estimates for FFO of $0.13 per share.

Occupancy

As of January 31, 2017, IRET reported that Occupancy decreased in the multifamily and healthcare segments by 2.3% and 2.6%, respectively, on a same-store basis.

Development Project in Progress

IRET noted that its Monticello Crossings is a 202 unit, $32.1 million multifamily development project in Monticello, MN. As of January 31, 2017, 82.7% of the units were leased or committed. Subsequent to quarter end, the final phase of development was open for tenancy as of March 01, 2017. Stabilization at 90% occupancy is expected to be reached in Q1 FY18. During the reported quarter, no development projects were placed in service.

Value Add Program

IRET stated that for its value add program, the Company is committing an estimated $3.5 million per quarter to rehab approximately 1,500 units in FY17. Apartments will be remodeled as the leases expire and upgrades will include a variety of new appliances, flooring, lighting, kitchen cabinets, and bathroom upgrades. During Q3 FY17, IRET completed the remodeling of 267 units at an average cost of $9,983, bringing the total units renovated during the fiscal year to 726, which are achieving average rental rate increases of 12.8%.

Disposition Activity

During Q3 FY17, IRET disposed of five senior housing properties for a sale price of $69.9 million and a retail property for a sale price of $4.0 million, netting proceeds of $58.8 million. Subsequent to quarter end, IRET disposed of 18 senior housing properties for a total sale price of $115.6 million with a gain on sale of approximately $31.6 million, netting approximately $100.0 million in proceeds. Also subsequent to quarter end, IRET disposed of one medical office property for a sale price of $20.7 million with a gain on sale of approximately $6.2 million, netting approximately $20.0 million in proceeds, including a lease termination fee of $3.2 million.

Liquidity

At January 31, 2017, IRET had $57.0 million cash on hand and its operating partnership had funds available of $17.0 million from the $174.0 million credit limit on its line of credit, which matures January 31, 2021.

Quarterly Distributions

On January 17, 2017, IRET paid a quarterly distribution in the aggregate amount of $0.13 per common share and unit of IRET Properties. The distribution consisted of a regular quarterly distribution of $0.07 per share/unit and a special distribution of $0.06 per share/unit associated with capital gains from property disposition transactions. This was IRET’s 183rd consecutive distribution. Additionally, IRET’s Board of Trustees has declared quarterly distributions in the aggregate amount of $0.07 per share/unit, payable on April 03, 2017, to common shareholders and unit-holders of record at the close of business on March 20, 2017.

Outlook

For the fiscal year ending April 30, 2017, IRET’s management revised its estimate of FFO to a range of $0.41 to $0.43 per share/unit from the prior range of $0.48 to $0.52 per share/unit. This guidance revision reflects management’s view of current market conditions, and its assumption of Same-Store multifamily NOI growth of (4.0) % to (6.0) %, which is a revision from the prior range of (1.0) % to (3.0) %.

Stock Performance

At the close of trading session on Thursday, March 23, 2017, Investors Real Estate Trust’s stock price rose 1.23% to end the day at $5.74. A total volume of 448.96 thousand shares were exchanged during the session. The stock currently has a market cap of $699.82 million and has a dividend yield of 4.88%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458083

Upcoming AWS Coverage on New York & Co. Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. announces its post-earnings coverage on Genesco Inc. (NYSE: GCO) as the Company reported its financial results for its fourth quarter and fiscal 2017 on March 10, 2017. The footwear, hats, clothing, and accessories seller surpassed earnings estimates. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Genesco’s competitors within the Apparel Stores space, New York & Company, Inc. (NYSE: NWY), released its Q4 2016 and FY16 results after the market closed on Thursday, March 16, 2017. AWS will be initiating a research report on New York & Co. in the coming days.

Today, AWS is promoting its earnings coverage on GCO; touching on NWY. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

Genesco reported that net sales for the fourth quarter ended January 28, 2017, decreased 5% to $883.17 million from $932.21 million in Q4 FY16, reflecting the sale of the Lids Team Sports business in Q4 FY16 and a decline of 2%in sales from the remaining businesses. The Company’s revenue numbers came in below analysts’ consensus of 903.2 million.

Genesco’s consolidated comparable sales, including same store sales and comparable ecommerce and Catalog sales were flat in the reported quarter, with an 8% increase in the Lids Sports Group, a 6% decrease in the Journeys Group, a 2% increase in the Schuh Group, and a 1% decrease in the Johnston & Murphy Group. Comparable sales for the Company reflected a 2% decrease in same store sales and a 12% increase in ecommerce sales.

For Q4 FY17, Genesco’s gross margin improved 190 basis points to 47.3%, led by Lids and Schuh, where better results offset declines in Journeys. Gross margin for Lids improved approximately 700 basis points, partly reflecting the sale of Lids team sports, which was a lower margin business. The Company stated that improvement in the retail business was a very healthy 400 basis points, as Lids anniversaried its inventory rightsizing and a particularly intense level of clearance activity in Q4 FY16. During the reported quarter, Schuh’s gross margin improvement of 380 basis points was also significant as Schuh anniversaried very heavy promotional activity that resulted from last year’s difficult holiday season. Journey’s gross margin decreased 190 basis points.

For Q4 FY17, Genesco’s earnings from continuing operations were $46.54 million, or $2.40 per diluted share, compared to earnings from continuing operations of $44.66 million, or $2.07 per diluted share, for Q4 FY16. The reported quarter results reflected a $0.25 per diluted share gain after tax, including a gain on the sale of SureGrip Footwear of $12.3 million and a gain of $0.8 million on other legal matters, which was partially offset by $3.9 million of asset impairment charges, pension settlement expenses, and other items. Adjusted for certain items, earnings from continuing operations were $41.8 million, or $2.15 per diluted share, for Q4 FY17 compared to earnings from continuing operations of $45.8 million, or $2.11 per diluted share, for Q4 FY16. The Company’s earnings results smashed past Wall Street’s expectation of $1.79 per share.

Fiscal 2017 Results

For the year ended January 28, 2017, Genesco reported sales of $2.9 billion, down 5% compared to net sales of $3.0 billion for the year ended January 30, 2016, reflecting the sale of the Lids Team Sports business and a 1% declined in sales from the remaining businesses.

Genesco’s earnings from continuing operations for FY17 were $97.9 million, or $4.85 per diluted share, compared to earnings from continuing operations of $95.4 million, or $4.15 per diluted share, for FY16. On an adjusted basis, the Company reported earnings from continuing operations of $87.2 million, or $4.33 per diluted share, for FY17, compared to earnings from continuing operations of $98.6 million, or $4.29 per diluted share, for the year ago period.

Balance Sheet

In Q4 FY17, Genesco’s total inventory was up 6%, or $34 million, on a sales decrease of 2%. This increase at year-end was attributable primarily to Journeys and to Lids. Journeys’ inventory was up, as anticipated, 10%, or $23 million, on a sales decrease of 3%. This was due to almost $40 million of new receipts in January. Capital expenditures for Q4 FY17 were $28 million and depreciation and amortization was $19 million.

In FY17, Genesco repurchased a total of 2.2 million shares of common stock for a total cost of $133 million and an average price of $61.81 per share. The Company did not repurchase any shares in Q4 FY17. Through the end of February 2017, the Company had repurchased 138,900 shares at a total cost of $8 million and an average price of $59.49.

Outlook

For FY18, Genesco expects adjusted diluted earnings per share in the range of $4.40 to $4.55.These expectations do not include expected non-cash asset impairments and other charges, estimated in the range of $0.22 to $0.26 per share after tax, for the full fiscal year.

Stock Performance

At the closing bell, on Thursday, March 23, 2017, Genesco’s stock rose slightly by 0.90%, ending the trading session at $55.75. A total volume of 275.46 thousand shares were traded at the end of the day, which was higher than the 3-month average volume of 237.19 thousand shares. In previous six months, shares of the Company have advanced 7.42%. Shares of the company have a PE ratio of 11.32. At Thursday’s closing price, the stock’s net capitalization stands at $1.11 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458080

Upcoming AWS Coverage on Teekay LNG Partners Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. blog coverage looks at the headline from DHT Holdings, Inc. (NYSE: DHT) as the Company announced on March 23, 2017, the acquisition of BW Group’s very large crude carriers (VLCC) fleet, including the two newbuildings due for delivery in 2018. The transaction is valued at $538 million for the 11 VLCCs DHT plans to acquire from BW Group. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of DHT Holdings’ competitors within the Shipping space, Teekay GP L.L.C., the general partner of Teekay LNG Partners L.P. (NYSE: TGP) reported the Partnership’s results for the quarter and year ended December 31, 2016.. AWS will be initiating a research report on Teekay LNG Partners in the coming days.

Today, AWS is promoting its blog coverage on DHT; touching on TGP. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

Breaking down the Agreement

BW Group’s VLCC fleet is currently valued at about $538 million at prevailing broker valuations. DHT plans to finance the acquisition by issuing approximately $256 million of DHT’s capital stock, consisting of $32 million shares of DHT’s common stock and 15,700 shares of preferred stock that are mandatorily convertible into 15.7 million shares of DHT’s common stock subject to DHT’s shareholders’ approval. The implied value of DHT’s common stock issued to BW Group is valued at $5.37 per share. Additionally, DHT will pay BW Group $177.36 million in cash and assume approximately $104.16 million in remaining obligations (the two newbuildings).

Sale of Old VLCCs

On March 17, 2017, DHT announced that it has entered into an agreement to sell the DHT Ann, 2001 built by VLCC for about $24.8 million. This step was viewed as a step to renew the existing fleet and replace it with the new ones at the end of the transaction. The Company will deliver the vessel to its new owners by Q2 FY17. This agreement with BW Group is viewed as the next step of the definitive fleet renewal strategy. DHT Holdings has been a recent acquisition target, when Frontline Ltd (NYSE: FRO) made two proposals, both of which were rejected, to acquire the Company at an exchange ratio of 0.8 Frontline’s shares for each DHT’s share on February 28, 2017.

The VLCC Newbuildings case

DHT announced on March 15, 2016, that it took delivery of a VLCC newbuilding from Hyundai Heavy Industries. Named as DHT Lion, this new building entered the spot market and was the third in a series of six VLCC newbuildings to be delivered from November 2015 to October 2016. The next newbuilding was delivered in July 2016, as per schedule. Post this announcement, DHT Holdings announced on March 01, 2017 that it has secured bank financing for the two 318,000 dwt VLCC newbuildings with scheduled delivery in July and September 2018 from Hyundai Heavy Industries. DHT reportedly financed 50% of the contract price where the remainder was financed by cash at hand. DHT will pay $177.36 million in cash and take over $104.6 million in debt on these two newbuildings.

DHT’s Growth Portfolio

DHT in the recent years has aimed at renewing its fleet of VLCCs in an attempt to generate greater value for the shareholders. Being a leading crude oil tanker Company, DHT is set to become one of the world’s largest independent VLCC owners. Following BW Group’s delivery of all the vessels and novation of newbuilding contracts to DHT, BW Group and its affiliates will own nearly 33.5% of DHT’s outstanding share capital and will be granted customary rights. Additionally, at the end of this transaction, DHT will have a fleet of 30 VLCCs, including four newbuildings with scheduled delivery in 2018.

Stock Performance

At the close of trading session on Thursday, March 23, 2017, DHT Holdings’ share price finished yesterday’s trading session at $4.49, tumbling 7.61%. A total volume of 3.90 million shares exchanged hands, which was higher than the 3 months average volume of 1.88 million shares. The stock has rallied 15.27% and 10.86% in the last three months and past six months, respectively. Furthermore, since the start of the year, shares of the Company have surged 10.25%. The stock currently has a market cap of $419.50 million and has a dividend yield of 7.13%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458082

Upcoming AWS Coverage on Jazz Pharmaceuticals Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. blog coverage looks at the headline from Stemline Therapeutics, Inc. (NASDAQ: STML) as the Company announced on March 23, 2017, that enrolment of Stage 3 in the SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been completed. The Company also reviewed key milestones for the SL-401 program over the coming year. Stemline is a clinical stage biopharmaceutical Company developing novel therapeutics for oncology indications of unmet medical need. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Stemline Therapeutics’ competitors within the Biotechnology space, Jazz Pharmaceuticals PLC (NYSE: JAZZ), reported on February 28, 2017, its financial results for the full year and the fourth quarter of 2016 and provided financial guidance for 2017. AWS will be initiating a research report on Jazz Pharma in the coming days.

Today, AWS is promoting its blog coverage on STML; touching on JAZZ. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

Stage 3 Enrollment

Stemline has completed enrolment of the Stage 3 cohort of the SL-401 pivotal trial in BPDCN. The Company has enrolled 13 first-line BPDCN patients for the Stage III trials. The Company stated that the statistical analysis will be based on evaluable first-line patients. The registration pathway was as per its agreement with the U.S. Food and Drug Administration (FDA). Based on the data outcome of the trial, Stemline plans to use the results generated to support the potential filing of a Biologics License Application (BLA) for full approval in first-line BPDCN, and is targeting possible BLA filing in H2 2017.

For the Stage III multicenter, pivotal trial Stemline has enrolled 47 BPDCN patients at seven centers in the US. The 47 BPDCN patients were comprised of 32 first-line patients and 15 relapsed/refractory patients dosed at 12 ug/kg/day. Stemline plans to provide a clinical update on patients enrolled in Stages 1 and 2 at a medical conference around mid-year, with top-line data from Stage 3 expected in H2 2017. Stemline plans to continue to enroll both first-line and relapsed/refractory BPDCN patients under the current protocol. SL-401 received Breakthrough Therapy Designation (BTD) by the FDA in August 2016.

BLA Preparation and Pre-Commercial Activities

Stemline announced that its clinical, preclinical, manufacturing, and regulatory teams are working toward a timely and comprehensive potential BLA filing. Ongoing efforts include compiling the necessary supportive data and assembling the BLA modules, including clinical, clinical pharmacology, non-clinical, and CMC (chemistry, manufacturing, and controls). In parallel, the Company’s commercial team is working to define the BPDCN market landscape, including factors related to patient flow, market access and pricing considerations, all with an eye toward setting the stage for a successful launch of SL-401, if approved.

Other Trial Updates

Stemline is performing additional Phase 2 trials with SL-401 and is enrolling patients with other malignancies including high-risk myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML) in remission with minimal residual disease (MRD). A Phase 1/2 trial of SL-401 in combination with pomalidomide is enrolling patients with relapsed/refractory multiple myeloma. The Company also has a Phase 1 dose escalation trial and is enrolling patients with advanced tumors with SL-801, a novel oral small molecule reversible inhibitor of XPO1. A Phase 2 trial with SL-701, an immunotherapy designed to activate the immune system to attack tumors has completed dosing and patients with second-line glioblastoma are being followed for survival.

Financial Results

On March 16, 2017, Stemline announced that for Q4 FY16 it had a net loss of $10.0 million, or $0.56 per share, compared with a net loss of $10.2 million, or $0.58 per share, for Q4 FY15. The Company’s Research and development expenses were $7.3 million for Q4 FY16, which reflects a drop of 8%, compared with $7.9 million for Q4 FY15.

Stemline ended Q4 FY16 with $67.6 million in cash, cash equivalents, and investments compared to $74.3 million as of September 30, 2016, which reflects a cash burn of $6.7 million for the reported quarter. Subsequent to year end 2016, Stemline completed a follow-on public offering during January 2017 raising $48.2 million in net cash proceeds bringing total cash, cash equivalents, and investments to approximately $110.0 million as of March 16, 2017.

Stock Performance

At the closing bell, on Thursday, March 23, 2017, Stemline Therapeutics’ stock dropped 5.03%, ending the trading session at $8.50. A total volume of 365.52 thousand shares were traded at the end of the day. In the last month and previous twelve months, shares of the Company have surged 27.82% and 83.98%, respectively. At Thursday’s closing price, the stock’s net capitalization stands at $212.93 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458081

CAMBRIDGE, MA / ACCESSWIRE / March 24, 2017 / Myomo, Inc., (“Myomo” or the “Company”), a commercial stage medical robotics company, announced today that it is hosting a live, interactive webinar of the Company’s $15 million Reg A+ IPO investment opportunity, followed by a Q&A with Myomo CEO, Paul R. Gudonis. The investor webinar will take place on Tuesday, March 28th at 2:00pm EDT.

Myomo’s investor webinar will include discussion on the Company’s plans for growth as well as its non-invasive technology, exclusively licensed from Massachusetts Institute of Technology, which restores a patient’s ability to use their partially paralyzed or weakened arms and hands again so they can return to work, live independently and reduce their cost of care. Due to the large number of strokes, spinal cord injuries, and other neurological conditions that occur each year, the MyoPro® has the capability to help millions of individuals worldwide.

“We are very excited to share our vision of restoring upper limbs to the large number of individuals impacted by paralysis with a broad set of individual investors that now have the opportunity to invest in our Company, alongside accredited investors and institutions, at our initial offering price,” said Mr. Gudonis. “While a traditional public offering is generally reserved for large institutions and the Wall Street elite to invest at this stage, we are taking advantage of new SEC regulations to level the playing field for all investors to participate concurrently in our IPO.”

The Company seeks to raise up to $15 million in its IPO under Regulation A+ and then, in succession and subject to NYSE requirements, be listed on the NYSE MKT as “MYO.” TriPoint Global Equities, LLC, working with its online division BANQ® (www.banq.co), will act as the lead managing selling agent and bookrunner for the offering. Myomo intends to use the proceeds from the offering to fund sales and marketing, product development, repayment of debt, and for working capital and other general corporate purposes. To learn more about the IPO or to invest visit www.banq.co/listings/myomo

To register for the webinar, please visit http://events.shindig.com/event/tripointmyomo.

About Myomo, Inc.

Myomo, Inc. is a commercial stage medical robotics Company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Based on patented technology developed at MIT and the Company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuromuscular disability such as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). It is provided through clinical relationships with VA medical centers, leading rehabilitation hospitals, and Orthotics and Prosthetics (“O&P”) practices. Several hundred have been successfully used by patients. It is the only device that, sensing a patient’s own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.

About BANQ(R) and TriPoint

Tripoint Global Equities, LLC (“TriPoint”), a FINRA member firm, is a boutique investment bank, with corporate finance and sales and trading services. TriPoint focuses on providing U.S. and non-U.S. companies of up to $500 million in revenue with capital raising, corporate finance advisory services and assistance with navigating the regulatory environment for companies listing on the U.S. markets. TriPoint Global maintains specialized practices in institutional private placements, sales and trading, mergers and acquisitions, and corporate finance. BANQ®, the online division of TriPoint, www.banq.co, is an electronic investment banking platform that streamlines the matching of investors with quality growth companies and alternative investment opportunities. BANQ® provides investors access to exciting companies with exposure to rapidly growing sectors and new technologies. BANQ® takes the entire public and private offering process digital and online, providing access to U.S. opportunities and offerings in the U.S. markets. BANQ® widely markets its offerings utilizing the new general solicitation and advertising rules promulgated by the U.S. Securities & Exchange Commission, in response to the passage of the JOBS Act of 2012 including Reg A+ and Reg D. TriPoint has offices in New York City, Jericho, NY, Akron, OH, Beijing China and Washington D.C. For more information, please visit http://www.tripointglobalequities.com.

Myomo Inc.’s offering statement for its initial public offering under Regulation A has been qualified by the Securities and Exchange Commission. The securities offered by Myomo Inc. are highly speculative. Investing in shares of Myomo Inc. involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. To obtain a copy of the Offering Circular, go to Myomo Form 1-A at https://goo.gl/z7npq1.

Forward-Looking Statements

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the Company, expressed by such language as “expected,” “anticipated,” “projected” and “forecasted.” Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the Company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events.

To Inquire for BANQ(R) Services:

inquiries@banq.co

www.banq.co

SOURCE: Myomo, Inc.

ReleaseID: 458096

Upcoming AWS Coverage on DICK’S Sporting Goods Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. announces its post-earnings coverage on Hibbett Sports, Inc. (NASDAQ: HIBB). The Company released its financial results for its fourth quarter and fiscal year 2017 on March 10, 2017. The athletic specialty retailer’s sales increased 0.5% and it also provided FY18 outlook. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Hibbett Sports’ competitors within the Sporting Goods Stores space, DICK’S Sporting Goods, Inc. (NYSE: DKS), reported on March 07, 2017, its earnings results for the fourth quarter and full year ended January 28, 2017. AWS will be initiating a research report on DICK’S Sporting Goods in the coming days.

Today, AWS is promoting its earnings coverage on HIBB; touching on DKS. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

For the 13-week period ended January 28, 2017, Hibbett’s net sales increased 0.5% to $246.9 million compared with $245.7 million for the 13-week period ended January 30, 2016. The Company’s revenue numbers was slightly below analysts’ consensus estimates of $247 million. Hibbett’s comparable store sales decreased 2.2%. The Company stated that apparel and equipment both experienced declines in comparable store sales, while footwear continued to show stronger sales with a mid-single digit increase.

For Q4 FY17, Hibbett’s gross profit was 33.0% of net sales compared with 34.8% for Q4 FY16. The decrease was mainly due to markdowns taken to reduce inventory, a negative effect of product mix due to higher footwear sales, and de-leverage of logistics and store occupancy expenses associated with lower comparable store sales.

Hibbett’s store operating, selling, and administrative expenses were 23.2% of net sales for Q4 FY17 compared with 21.8% of net sales for Q4 FY17. The increase was mainly due to de-leverage associated with lower comparable store sales and continued investments in the Company’s omni-channel initiative.

For Q4 FY17, Hibbett’s net income totaled $12.1 million compared with $17.4 million for Q4 FY16. The Company’s earnings per diluted share were $0.54 for the reported quarter, compared with $0.76 for the year earlier period. Hibbett’s earnings numbers met market estimates of $0.54 per share.

Fiscal 2017 Results

For the 52-week period ended January 28, 2017, Hibbett’s net sales increased 3.2% to $973.0 million compared with $943.1 million for the 52-week period ended January 30, 2016. Comparable store sales increased 0.2%. The Company’s gross profit was 34.8% of net sales for the reported quarter compared with 35.3% for the prior year’s same period.

Hibbett’s net income for Q4 FY17 was $61.1 million compared with $70.5 million for Q4 FY16. The Company’s earnings per diluted share were $2.72 for the reported quarter compared with $2.92 for the year ago comparable period.

Store Update

For the year, Hibbett opened 65 new stores, expanded 8 high-performing stores and closed 31 underperforming stores, bringing the store base to 1,078 in 35 states as of January 28, 2017.

Liquidity and Stock Repurchases

Hibbett ended Q4 FY17 with $39.0 million of available cash and cash equivalents on the consolidated balance sheet, no bank debt outstanding, and full availability under its $80.0 million unsecured credit facilities.

During the reported quarter, the Company repurchased 324,200 shares of common stock for a total expenditure of $11.4 million. Approximately $257.9 million of the total authorization remained for future stock repurchases as of January 28, 2017.

Fiscal 2018 Outlook

For FY18, which will have 53 weeks versus 52 weeks in FY17, Hibbett is forecasting earnings per diluted share in the range of $2.65 to $2.85, including an increase of approximately $0.09 to $0.11 per diluted share due to the 53rd week. The Company is expecting a negative impact of $0.03 to $0.04 per diluted share due to its omni-channel initiative. Hibbett is forecasting an increase in comparable store sales in the low-single digit range. The Company is expecting approximately 50 to 60 new store openings with approximately 25 to 35 store closures. Hibbett is estimating capital expenditures of approximately $25 million to $30 million and share buyback of approximately $45 million to $55 million for the year.

Stock Performance

At the close of trading session on Thursday, March 23, 2017, Hibbett Sports’ stock price slightly fell 0.17% to end the day at $28.70. A total volume of 275.38 thousand shares were exchanged during the session. The stock currently has a market cap of $630.25 million and is trading at a PE ratio of 10.59.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458093

Upcoming AWS Coverage on Crescent Point Energy Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. announces its post-earnings coverage on Extraction Oil & Gas, LLC (NASDAQ: XOG). The Company announced its financial results for the fourth quarter fiscal 2016 (Q4 FY16) and full year fiscal 2016 (FY16) on March 13, 2017. The Denver, Colorado-based Company’s quarterly total revenues surged 69% y-o-y, beating Wall Street’s estimates. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Extraction Oil & Gas’ competitors within the Independent Oil & Gas space, Crescent Point Energy Corp. (NYSE: CPG), reported on February 23, 2017, its financial results for the year ended December 31, 2016. AWS will be initiating a research report on Crescent Point Energy in the coming days.

Today, AWS is promoting its earnings coverage on XOG; touching on CPG. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

During Q4 FY16, Extraction Oil & Gas’s total revenues came in at $94.69 million, which was above the $56.12 million recorded at the end of Q4 FY15. Total revenues for the reported quarter topped market consensus estimates of $88.34 million. The Company generated $58.16 million from oil sales in Q4 FY16 compared to $42.26 million in Q4 FY15. Natural gas sales revenues increased to $20.92 million in Q4 FY16 from $8.31 million in Q4 FY15. Furthermore, revenues from Natural gas liquids (NGL) sales grew to $15.60 million in Q4 FY16 from $5.55 million in Q4 FY15.

The oil and gas Company reported net loss of $245.60 million, or $1.54 loss per diluted share, in Q4 FY16 compared to net loss of $9.20 million in Q4 FY15. Market analysts ecpected the Company to report net loss of $0.18 per diluted share for Q4 FY16.

For full year FY16, Extraction Oil & Gas operating total revenues stood at $278.09 million, rising 41% from $197.75 million reported in FY15. The Company’s net loss during FY16 was $456.00 million, or $1.54 loss per diluted share, versus net loss of $47.26 million in FY15.

Operating Metrics

Extraction Oil & Gas’s total operating expenses increased during Q4 FY16 to $320.39 million from $92.27 million in the past year’s comparable quarter. The Company’s operating loss widened during Q4 FY16 to $225.70 million from $36.15 million in Q4 FY15. In the reported quarter, the Company incurred total other expenses of $49.19 million Q4 FY16 compared to total other income of $26.95 million in Q4 FY15. Furthermore, loss before income taxes for Q4 FY16 stood at $274.88 million versus $9.20 million in the year ago same period.

In Q4 FY16, Extraction Oil & Gas’s oil sales volume increased to 1,479 thousand barrels (MBbl), from 1,153 MBbl in Q4 FY15. The quarterly sales volume of natural gas totaled 7,360 million cubic feet (MMcf) in Q4 FY16 compared to 3,598 MMcf in the prior year comparable quarter. NGL sales volume also increased during Q4 FY16 to 805 MBbl from 477 MBbl in Q4 FY15. Furthermore, total sales during the reported quarter was 3,511 thousand barrels of oil equivalent (MBoe) compared to 2,230 MBOE in Q4 FY15. Meanwhile, average sales in Q4 FY16 was 38,161 barrels of oil equivalent per day (BOE/d), compared to 24,243 BOE/d in Q4 FY15.

Cash Matters and Balance Sheet

In the year ended on December 31, 2016, Extraction Oil & Gas’ operating activities generated $116.39 million as net cash compared to $166.68 million in the prior year. The Company’s cash and cash equivalents balance surged to $588.74 million as on December 31, 2016, from $97.11 million at the close of books on December 31, 2015.

IPO

On October 11, 2016, Extraction Oil & Gas had announced the pricing of its initial public offering of 33.33 million shares of its common stock at $19.00 per share. The Company had initially estimated the offering price range of $15.00 to $18.00. The shares had started trading on October 12, 2016 on the NASDAQ Global Select Market under the ticker symbol “XOG.”

Guidance

For full year FY17, Extraction Oil & Gas reaffirm its previously disclosed operational guidance. The Company continues to expect FY17 net sales volumes to average between 48 MBoe/d and 54 MBoe/d with crude oil production range of 23 MBbl/d to 26 MBbl/d.

For Q1 FY17, the Company estimates net sales volumes to be between 31 MBoe/d to 33 MBoe/d with oil average sales volumes in the range of 12 MBbl/d to14 MBbl/d.

Stock Performance

At the close of trading session on Thursday, March 23, 2017, Extraction Oil & Gas’ stock price rose 1.20% from its previous closing price of $16.62, to end the day at $16.82. A total volume of 831.12 thousand shares were exchanged during the session. The stock currently has a market cap of $2.89 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458090

Upcoming AWS Coverage on ACADIA Pharmaceuticals Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. blog coverage looks at the headline from Egalet Corp. (NASDAQ: EGLT) as the Company announced on March 23, 2017, that it has received new US and international patents for the Company’s proprietary Guardian™ Technology. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Egalet’s competitors within the Biotechnology space, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), reported on February 28, 2017, its financial results for Q4 and year ended December 31, 2016. AWS will be initiating a research report on ACADIA Pharma in the coming days.

Today, AWS is promoting its blog coverage on EGLT; touching on ACAD. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

Patent Details

Egalet announced that the United States Patent and Trademark Office (USPTO) has issued patent number 9,549,899 covering ARYMO™ ER (morphine sulfate) extended-release tablets for oral use only –CII developed using the Company’s proprietary Guardian Technology. It is the second US patent covering ARYMO ER. The patent offers protection through 2033 and is listed in the Orange Book.

Egalet stated that it has been issued European patent number 239348, which and offers protection of products developed using Guardian Technology. Also issued is Australian patent number 2015200243. It is the third in a patent family. Both the European and Australian patents offer protection through 2030.

Egalet announced that it was also issued Canadian patent number 2,751,667, which covers Guardian Technology’s immediate-release system designed to slow the release of the active pharmaceutical ingredient in the presence of alcohol. The patent offers protection through 2030.

“The newly issued patents further strengthen our ability to grow our business through the development of immediate- and extended-release products using our Guardian Technology,” said Mark Strobeck, Ph.D., Egalet’s Executive Vice President and Chief Operating Officer.

Egalet has been granted a total of 18 US patents and 95 patents outside of the US that cover Guardian Technology and its product candidates.

Guardian™ Technology

Egalet’s proprietary Guardian Technology is a polymer matrix tablet technology that utilizes a novel application of the well characterized manufacturing process of injection molding, which results in tablets that are hard and difficult to manipulate for misuse and abuse. Tablets manufactured with Guardian Technology have been shown to have increased resistance to physical methods of manipulation, such as cutting, crushing, grinding or breaking, using a variety of mechanical and electrical tools. They are also resistant to chemical manipulation and attempts at extraction and turn into a viscous hydrogel on contact with liquid, making syringeability very difficult.

Financial Results

On March 09, 2017, Egalet announced its fourth quarter and fiscal 2016 results. The Company reported net product sales of $6.1 million for the quarter ended December 31, 2016 compared to $2.1 million for the same period in 2015 and net product sales of $16.9 million for the year ended December 31, 2016, compared to $4.2 million for FY15. As of December 31, 2016, Egalet had cash and marketable securities totaling $86.8 million.

For Q4 FY16, Egalet posted net loss of $21.4 million, or $0.87 per share, compared to a net loss of $6.8 million, or $0.28 per share, for Q4 FY15. For FY16, the Company posted net loss of $90.6 million, or $3.70 per share, compared to a net loss of $57.9 million, or $2.94 per share, for FY15.

Stock Performance

At the close of trading session on Thursday, March 23, 2017, Egalet’s stock price climbed 3.25% to end the day at $4.77. A total volume of 489.60 thousand shares were exchanged during the session. The stock currently has a market cap of $120.25 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458089

Upcoming AWS Coverage on Lear

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. blog coverage looks at the headline from Superior Industries International, Inc. (NYSE: SUP) as the Company announced on March 23, 2017, that it will commence a tender offer to acquire all the outstanding shares of UNIWHEELS AG. Superior Industries is the largest manufacturer of aluminum wheels for light vehicles in North America. The Company will execute the agreement, at an aggregate equity purchase price, of approximately $715 million. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Superior Industries International’s competitors within the Auto Parts space, Lear Corp. (NYSE: LEA), is estimated to report earnings on April 26, 2017. AWS will be initiating a research report on Lear following the release of its next earnings results.

Today, AWS is promoting its blog coverage on SUP; touching on LEA. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

Breaking down the acquisition

UNIWHEELS, headquartered in Germany, is currently the third largest supplier of aluminum wheels to the European OEM automotive market and Europe’s leading manufacturer of aluminum wheels for the automotive aftermarket. This transaction will immediately establish Superior Industries as the leading global supplier of aluminum wheels while diversifying its customer-base and end markets. The acquisition will expand Superior Industries’ geographic reach and offer a platform to better serve the global customers.

This transaction will be funded through a combination of debt, preferred equity, and balance sheet cash. The transaction has been approved by the Board of Directors of Superior Industries and UNIWHEELS Malta where the tender offer is expected to close around the end of May 2017.

Strategic Output of the Transaction

This agreement is viewed as a transformational step where it will create the largest global providers of aluminum wheels for the automotive OEM market while offering access to a premium client base, including the likes of BMW, Mercedes, Volkswagen, and other carmakers. The transaction will help Superior Industries leverage the extensive global manufacturing capacity of the combined venture, hence creating a larger platform for further investment to deliver greater value.

Superior Industries primarily operates in North America while UNIWHEELS is the leading aftermarket aluminum wheel manufacturer in Europe. This transaction will deliver simultaneous benefits for both units. The agreement is immediately accretive to EPS where Superior Industries anticipates $15 million in annual run-rate synergies by 2020. Sales and volumes are set to be balanced midst the two primary markets, North America and Europe.

Terms of the Agreement

Under terms of the agreement, UNIWHEELS Malta will receive cash consideration of 226.5zl per share post the close of the tender offer. The Company’s public shareholders are set to receive cash consideration of approximately 236zl per share, equivalent to the volume-weighted-average-price for the prior 3 months. Superior Industries will commence a tender offer for 100% of the outstanding shares of UNIWHEELS.

Financing

The transaction to acquire 100% outstanding shares of UNIWHEELS is to be financed with about $660 million of newly funded debt, consisting of $400 million Senior Secured Term Loan B and $260 million of Senior Unsecured Notes, as well as $150 million of Preferred Equity, consisting of $100 million of Series A convertible redeemable preferred stock and $50 million of Series B preferred stock. Following the completion of the transaction, Superior Industries anticipates that it will reduce its annual dividend from $0.72 per share to $0.36 per share.

Superior’s Growth Prospects

This deal is a formidable step under Don Stebbins’ (the CEO of Superior Industries) strategy to expand North America’s largest wheelmaker. Stebbins has been slashing operating expenses by nearly $50 million between FY14 and FY16. Stebbins’s leadership has helped increase the Company’s income to more than $41 million for FY16 from $22.8 million for FY13. Superior Industries is offering $57.20 per share for the shares held by UNIWHEELS Holding and $59.60 per share for the public shares.

Stock Performance

At the closing bell, on Thursday, March 23, 2017, Superior Industries International’s share price finished yesterday’s trading session at $25.60, rising 2.40%. A total volume of 419.18 thousand shares exchanged hands, which was higher than the 3 months average volume of 145.44 thousand shares. The stock has advanced 8.47% and 19.55% in the last month and past twelve months, respectively. The stock is trading at a PE ratio of 15.81 and has a dividend yield of 2.81%. The net market capital for the Company’s stock stood at $638.46 million as per Thursday’s valuation.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458091